Cierre de la orejuela izquierda frente a anticoagulantes orales en FA e implante de stents coronarios. Registro DESAFIO

  1. José Ramón López Mínguez 1
  2. Estrella Suárez Corchuelo 1
  3. Sergio López Tejero 2
  4. Luis Nombela Franco 3
  5. Xavier Freixa 4
  6. Guillermo Bastos Fernández 5
  7. Xavier Millan 6
  8. Raúl Moreno Gómez 7
  9. José Antonio Fernández Díaz 8
  10. Ignacio Amat Santos 9
  11. Tomás Benito González 10
  12. Fernando Alfonso Manterola 11
  13. Pablo Salinas Sanguino 3
  14. Pedro L. Cepas Guillén 4
  15. Dabit Arzamendi 6
  16. Ignacio Cruz González 2
  17. Juan Manuel Nogales Asensio 1
  1. 1 Sección de Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario de Badajoz, Badajoz, España
  2. 2 Sección de Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
  3. 3 Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), España
  4. 4 Sección de Cardiología Intervencionista, Servicio de Cardiología, Instituto Cardiovascular, Hospital Clínico San Carlos Madrid, España
  5. 5 Sección de Cardiología Intervencionista, Servicio de Cardiología, Hospital Clínico de Barcelona, Barcelona, España
  6. 6 Sección de Cardiología Intervencionista, Servicio de Cardiología, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, España
  7. 7 Sección de Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, España
  8. 8 Sección de Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario de La Paz, IdiPAZ, Madrid, España
  9. 9 Sección de Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario de Puerta de Hierro, Majadahonda, Madrid, España
  10. 10 Sección de Cardiología Intervencionista, Servicio de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, España
  11. 11 Sección de Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario de León, León, España
Mostrar afiliacións +
Revista:
REC: Interventional Cardiology

ISSN: 2604-7276,  2604-7306

Ano de publicación: 2023

Volume: 5

Número: 4

Páxinas: 287-296

Tipo: Artigo

DOI: 10.24875/RECIC.M23000386 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Outras publicacións en: REC: Interventional Cardiology

Obxectivos de Desenvolvemento Sustentable

Resumo

Introduction and objectives: The treatment of patients with non-valvular atrial fibrillation (NVAF) who need coronary stenting is challenging. The objective of the study was to determine whether left atrial appendage occlusion (LAAO) could be a feasible option and benefit these patients. To this end, we studied the impact of LAAO plus antiplatelet drugs vs oral anticoagulants (OAC) (including direct OAC) plus antiplatelet drugs in these patients’ long-term outcomes. Methods: The results of 207 consecutive patients with NVAF who underwent coronary stenting were analyzed. A total of 146 patients were treated with OAC (75 with acenocoumarol, 71 with direct OAC) while 61 underwent LAAO. The median follow-up was 35 months. Patients also received antiplatelet therapy as prescribed by their cardiologist. The study received the proper ethical oversight. Results: Age (mean 75.7 years), and the past medical history of stroke were similar in both groups. However, the LAAO group had more unfavorable characteristics (history of coronary artery disease [CHA2DS2-VASc], and significant bleeding [BARC ≥ 2] and HAS-BLED). The occurrence of major adverse events (death, stroke/transient ischemic events, major bleeding) and major cardiovascular events (cardiac death, stroke/transient ischemic attack, and myocardial infarction) were significantly higher in the OAC group compared to the LAAO group: 19.75% vs 9.06% (HR, 2.18; P = .008) and 6.37% vs 1.91% (HR, 3.34; P = .037), respectively. Conclusions: In patients with NVAF undergoing coronary stenting, LAAO plus antiplatelet therapy produced better long-term outcomes compared to treatment with OAC plus antiplatelet therapy despite the unfavorable baseline characteristics of the LAAO group.

Referencias bibliográficas

  • 1. Leon MB, Baim DS, Popma JJ, et al. A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting. N Engl J Med. 1998;339:1665-1671.
  • 2. Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137:e67-e492.
  • 3. Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One. 2011;6:e24964-e24964.
  • 4. González-Pacheco H, Márquez MF, Arias-Mendoza A, et al. Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation. J Cardiol. 2015;66:148-154.
  • 5. Rohla M, Vennekate CK, Tentzeris I, et al. Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. Int J Cardiol. 2015;184:108-114.
  • 6. Généreux P, Giustino G, Witzenbichler B, et al. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2015;66:1036-1045.
  • 7. Busu T, Khan SU, Alhajji M, Alqahtani F, Holmes DR, Alkhouli M. Observed versus Expected Ischemic and Bleeding Events Following Left Atrial Appendage Occlusion. Am J Cardiol. 2020;125:1644-1650.
  • 8. Osmancik P, Herman D, Neuzil P, et al. 4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation. J Am Coll Cardiol. 2022;79:1-14.
  • 9. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure. J Am Coll Cardiol.. 2017;70:2964-2975.
  • 10. Mehran R, Rao SV, Bhatt DL, et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation. 2011;123:2736-2747.
  • 11. Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Eng J Med. 2017;377:1513-1524.
  • 12. Capodanno D, Huber K, Mehran R, et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI. J Am Coll Cardiol. 2019;74:83-99.
  • 13. Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019;40:3757-3767.
  • 14. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Eng J Med. 2016;375:2423-2434.
  • 15. Lopes RD, Leonardi S, Wojdyla DM, et al. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation. 2020;141:781-783.
  • 16. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335-1343.
  • 17. Cheung CC, Nattel S, Macle L, Andrade JG. Management of Atrial Fibrillation in 2021: An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guidelines. Can J Cardiol. 2021;37:1607-1618.
  • 18. Bertrand ME, Legrand V, Boland J, et al. Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary Stenting. Circulation. 1998;98:1597-1603.
  • 19. López-Mínguez JR, Nogales-Asensio JM, Infante De Oliveira E, et al. Long-term Event Reduction After Left Atrial Appendage Closure. Results of the Iberian Registry II. Rev Esp Cardiol. 2019;72:449-455.
  • 20. Yao X, Abraham NS, Alexander GC, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5:e003074.
  • 21. Yudi MB, Clark DJ, Farouque O, et al. Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention. Am Heart J. 2019;212:134-143.
  • 22. Lee S, Monz BU, Clemens A, Brueckmann M, Lip GYH. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open. 2012;2:e001768.
  • 23. Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107-1115.
  • 24. López-Mínguez JR, Nogales-Asensio JM, Infante De Oliveira E, et al. Major Bleeding Predictors in Patients with Left Atrial Appendage Closure: The Iberian Registry II. J Clin Med. 2020;9:2295.
  • 25. Tarantini G, D’Amico G, Schmidt B, et al. The Impact of CHA2DS2-VASc and HAS-BLED Scores on Clinical Outcomes in the Amplatzer Amulet Study. JACC: Cardiovasc Interv. 2020;13:2099-2108.
Fonte de datos: Dialnet